Hypertension

RAS blockade, hyperkalemia and AKI—look and you will find

Aliskiren combined with other inhibitors of the renin–angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    US Food and Drug Administration. FDA approves new drug treatment for high blood pressure [online], (2007).

  2. 2

    Harel, Z. et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 344, e42 (2012).

    Article  Google Scholar 

  3. 3

    Gormley, K., Dong, Y. & Sagnella, G. A. Regulation of the epithelial sodium channel by accessory proteins. Biochem. J. 371, 1–14 (2003).

    CAS  Article  Google Scholar 

  4. 4

    Toto, R. D., Mitchell, H. C., Lee, H. C., Milam, C. & Pettinger, W. A. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann. Intern. Med. 115, 513–519 (1991).

    CAS  Article  Google Scholar 

  5. 5

    Mann, J. F. et al. for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann. Intern. Med. 151, 1–10 (2009).

    Article  Google Scholar 

  6. 6

    Ting, R. Z., Luk, A. O. & Chan, J. C. Treatment and landmark clinical trials for renoprotection. Contrib. Nephrol. 170, 184–195 (2011).

    CAS  Article  Google Scholar 

  7. 7

    Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641–2650 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543–551 (2004).

    CAS  Article  Google Scholar 

  9. 9

    Oparil, S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221–229 (2007).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Ethics declarations

Competing interests

R. D. Toto is a consultant for and has received research funding from Novartis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Toto, R. RAS blockade, hyperkalemia and AKI—look and you will find. Nat Rev Nephrol 8, 257–258 (2012). https://doi.org/10.1038/nrneph.2012.62

Download citation

Further reading